Login to Your Account



Companies to Develop Cancer Therapeutic Targets

Metamark, Janssen Biotech Ink Potential $365M Deal

By Marie Powers
Staff Writer

Tuesday, December 20, 2011
Privately held Metamark Genetics Inc. landed a big fish, inking a research, collaboration and license agreement with Johnson & Johnson subsidiary Janssen Biotech Inc. potentially worth $365 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription